ArticleFrontiers in pharmacology2024
Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system.International journal of clinical pharmacy · 2026Article
- Artificial Intelligence for Drug Safety Across the Lifecycle and Decision Type: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Safety signals of perfluorohexyloctane ophthalmic solution in patients with dry eye disease.Frontiers in medicine · 2026Article
- Article
- Real-world safety of maribavir: a retrospective study based on signal detection in the FDA adverse event reporting system.International journal of clinical pharmacy · 2025Article
- Unraveling the mechanisms of irAEs in endometrial cancer immunotherapy: insights from FAERS and scRNA-seq data.Scientific reports · 2025Article
- Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004-2024).BMC pharmacology & toxicology · 2025Article
- Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research.Pharmaceutics · 2025Review
- Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database.Frontiers in pharmacology · 2025Article
- Comprehensive disproportionality analysis of individual case safety reports associated with Janus kinase inhibitors in psoriasis and psoriatic arthritis using the FAERS database.Frontiers in immunology · 2025Article
- A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.